On the other hand, several studies have found that PTRF promotes progression and resistance to treatment in breast cancer, pancreatic cancer, glioblastomas, and colorectal cancer (Yi et al., 2013; Wang et al., 2014). This evidence concerns the gene CAVIN1 and colorectal cancer.